The Treatment of Borderline Lesion in Protocol Biopsies Did Not Improve the Outcome in Kidney Transplant Recipients.
Nephrology, Transplantation and Pathology, National Institute of Medical Sciences and Nutrition SZ, Mexico, Distrito Federal, Mexico.
Meeting: 2016 American Transplant Congress
Abstract number: 103
Keywords: Biopsy, Graft survival, Histology, Kidney transplantation
Session Information
Session Name: Concurrent Session: Delayed Graft Function and Protocol Biopsy
Session Type: Concurrent Session
Date: Sunday, June 12, 2016
Session Time: 4:30pm-6:00pm
Presentation Time: 5:42pm-5:54pm
Location: Room 302
Introduction. Up to 30% of patients with protocol biopsies and stable renal function have borderline lesions. His relationship with acute rejection remains uncertain, as does the decision to treat them. The aim of this study is to compare the outcome of patients with borderline lesions treated versus those who were not treated.
Methods. From January 2004 to January 2015, 519 transplants were performed. All patients with a previous immunological event were excluded. We included 104 patients with borderline lesion on protocol biopsy without dysfunction, performed within the first year after transplantation. Graft survival was analyzed according to whether they received treatment for the total population, and excluding those with pretransplant DSA. Descriptive statistics was used according to the variable level of measure. To analyzed graft survival Kaplan-Meier and Log Rank method were used.
RESULTS. 104 patients, 50% male, were analyzed. Mean age was 34.6±12.9y, 57.7% were transplanted from living donor. The main cause of CKD was unknown in 57 (54.8%). From the total of patients, 48.1% (50) received methylprednisolone pulses, 5.8%(6) immunosuppression optimization, and both treatments 8.7%(9), and those who has not received any treatment were 37.4% (39). Only 15.4% (16) had pretransplant DSA. The graft survival was not different for those treated patient (figure1), including when the type of treatment was analyzed, or when patient with pretransplant DSA were excluded. The bar graph shows the histological evolution according to treatment. From all patients, 23.1%(24) progressed to rejection.
Conclusions. In this study, the treatment of borderline lesion did not improve the outcome in kidney transplant patients. Even the type of treatment did not modify the graft outcome.
CITATION INFORMATION: Flores-Mendoza A, Marino-Vazquez L, Guichard-Romero A, Uribe-Uribe N, Rivera-Marfil R, Nuñez-Abreu A, Alberu J, Morales-Buenrostro L. The Treatment of Borderline Lesion in Protocol Biopsies Did Not Improve the Outcome in Kidney Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Flores-Mendoza A, Marino-Vazquez L, Guichard-Romero A, Uribe-Uribe N, Rivera-Marfil R, Nuñez-Abreu A, Alberu J, Morales-Buenrostro L. The Treatment of Borderline Lesion in Protocol Biopsies Did Not Improve the Outcome in Kidney Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/the-treatment-of-borderline-lesion-in-protocol-biopsies-did-not-improve-the-outcome-in-kidney-transplant-recipients/. Accessed May 11, 2025.« Back to 2016 American Transplant Congress